"Dexamethasone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory 9-fluoro-glucocorticoid.
| Descriptor ID |
D003907
|
| MeSH Number(s) |
D04.210.500.745.432.769.344 D04.210.500.908.238
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dexamethasone".
Below are MeSH descriptors whose meaning is more specific than "Dexamethasone".
This graph shows the total number of publications written about "Dexamethasone" by people in this website by year, and whether "Dexamethasone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 0 | 4 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 4 | 7 |
| 2000 | 3 | 0 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 6 | 7 |
| 2003 | 1 | 7 | 8 |
| 2004 | 3 | 2 | 5 |
| 2005 | 2 | 5 | 7 |
| 2006 | 4 | 3 | 7 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 1 | 4 | 5 |
| 2012 | 2 | 4 | 6 |
| 2013 | 3 | 2 | 5 |
| 2014 | 0 | 9 | 9 |
| 2015 | 5 | 6 | 11 |
| 2016 | 4 | 2 | 6 |
| 2017 | 2 | 4 | 6 |
| 2018 | 5 | 5 | 10 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 6 | 8 |
| 2021 | 1 | 7 | 8 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 2 | 4 |
| 2025 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dexamethasone" by people in Profiles.
-
Intrathecal Dexamethasone as a FIRES Extinguisher: A 12-Patient Clinical Experience with Usage of Intrathecal Dexamethasone for Febrile Infection-Related Epilepsy Syndrome. Neurocrit Care. 2025 Oct; 43(2):563-571.
-
Implementation of an Institutional Protocol for the Use of Intrathecal Dexamethasone for Treatment-Refractory Pediatric Neuroinflammatory Disease. Pediatr Neurol. 2025 Jul; 168:1-5.
-
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. Pediatr Blood Cancer. 2025 Jun; 72(6):e31680.
-
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1163-1170.
-
Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. Cancer Res. 2025 Mar 03; 85(5):875-893.
-
Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome. Ann Clin Transl Neurol. 2025 Apr; 12(4):871-875.
-
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626.
-
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025 Mar; 39(3):710-719.
-
Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial. J Natl Compr Canc Netw. 2025 Jan 07; 23(1).
-
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol. 2025 Mar; 100(3):402-407.